当前位置：
X-MOL 学术
›
J. Clin. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Non-Squamous EGFR-Wildtype NSCLC in the Phase 2 LUMINOSITY Trial
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2024-06-06 , DOI: 10.1200/jco.24.00720 D. Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan Goldman, Fedor Moiseenko, Elena Filippova, Irfan Cicin, Tudor Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope Bradbury, Mor Moskovitz, Nuran Katgi, Pascale Tomasini, Alona Zer, Nicolas Girard, Kristof Cuppens, Ji-Youn Han, Shang-Yin Wu, Shobhit Baijal, Aaron S. Mansfield, Chih-Hsi Kuo, Kazumi Nishino, Se-Hoon Lee, David Planchard, Christina Baik, Martha Li, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine Ratajczak, Shun Lu
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2024-06-06 , DOI: 10.1200/jco.24.00720 D. Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan Goldman, Fedor Moiseenko, Elena Filippova, Irfan Cicin, Tudor Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope Bradbury, Mor Moskovitz, Nuran Katgi, Pascale Tomasini, Alona Zer, Nicolas Girard, Kristof Cuppens, Ji-Youn Han, Shang-Yin Wu, Shobhit Baijal, Aaron S. Mansfield, Chih-Hsi Kuo, Kazumi Nishino, Se-Hoon Lee, David Planchard, Christina Baik, Martha Li, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine Ratajczak, Shun Lu
Journal of Clinical Oncology, Ahead of Print.
中文翻译：
2 期 LUMINOSITY 试验中 Telisotuzumab Vedotin 单药疗法治疗既往接受过 c-Met 蛋白过度表达的晚期非鳞状 EGFR 野生型 NSCLC 患者
临床肿瘤学杂志，印刷前。
更新日期：2024-06-07
中文翻译：
2 期 LUMINOSITY 试验中 Telisotuzumab Vedotin 单药疗法治疗既往接受过 c-Met 蛋白过度表达的晚期非鳞状 EGFR 野生型 NSCLC 患者
临床肿瘤学杂志，印刷前。
京公网安备 11010802027423号